Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


Phase III MAIA study of Darzalex + Revlimid + dexamethasone shows survival benefits in multiple myeloma – Janssen Biotech

Written by | 20 Jun 2021

The Janssen Pharmaceutical Companies of Johnson & Johnson announced overall survival (OS) results from the Phase III MAIA (NCT02252172) study showing the addition of Darzalex (daratumumab) to lenalidomide… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.